Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease

Elsa Diguet, Pierre Olivier Fernagut, Xing Wei, Yansheng Du, Richard Rouland, Christian Gross, Erwan Bezard, François Tison

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Minocycline has been shown to exert anti-inflammatory effects underlying its putative neuroprotective properties in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) mouse model of Parkinson's disease and in the R6/2 mouse model of Huntington's disease (HD). However, contradictory results have recently been reported. We report deleterious effects of minocycline in two phenotypic (toxic) models of Parkinson's disease and HD in monkey and mouse. Of seven MPTP-intoxicated female cynomolgus monkeys (0.2 mg/kg, i.v. until day 15), three received minocycline (200 mg b.i.d.). While placebo-MPTP-treated animals displayed mild parkinsonism at day 15, the minocycline/MPTP-treated animals tended to be more affected (P = 0.057) and showed a greater loss of putaminal dopaminergic nerve endings (P < 0.0001). In the 3-nitropropionic acid (3-NP) mouse model of HD, minocycline (45 mg/kg i.p.) was administered 30 min before each i.p. injection of 3-NP (b.i.d., cumulated dose, 360 mg/kg in 5 days). Mice receiving minocycline exhibited a worsening of the mean motor score with a slower recovery slope, more impaired general activity and significantly deteriorated performances on the rotarod, pole test and beam-traversing tasks. The histopathological outcome demonstrated that minocycline-treated mice presented significantly more severe neuronal cell loss in the dorsal striatum. The effect of minocycline vs. 3-NP was also investigated on hippocampal and cortical cell cultures, minocycline blocked 3-NP-induced neurotoxicity at certain doses (1 mM cortical neurons) but not at higher doses (10 mM). Thus, minocycline may have variable and even deleterious effects in different species and models according to the mode of administration and dose.

Original languageEnglish
Pages (from-to)3266-3276
Number of pages11
JournalEuropean Journal of Neuroscience
Volume19
Issue number12
DOIs
StatePublished - Jun 2004

Fingerprint

Minocycline
Huntington Disease
Parkinson Disease
Animal Models
Rotarod Performance Test
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Macaca fascicularis
Nerve Endings
Poisons
Parkinsonian Disorders
Haplorhini
Anti-Inflammatory Agents
Cell Culture Techniques
Placebos
Neurons

Keywords

  • 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
  • 3-nitropropionic acid
  • Minocycline
  • Monkey
  • Mouse
  • MPTP

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. / Diguet, Elsa; Fernagut, Pierre Olivier; Wei, Xing; Du, Yansheng; Rouland, Richard; Gross, Christian; Bezard, Erwan; Tison, François.

In: European Journal of Neuroscience, Vol. 19, No. 12, 06.2004, p. 3266-3276.

Research output: Contribution to journalArticle

Diguet, Elsa ; Fernagut, Pierre Olivier ; Wei, Xing ; Du, Yansheng ; Rouland, Richard ; Gross, Christian ; Bezard, Erwan ; Tison, François. / Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. In: European Journal of Neuroscience. 2004 ; Vol. 19, No. 12. pp. 3266-3276.
@article{c6fb13ac756643e7bb2eb79393794faf,
title = "Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease",
abstract = "Minocycline has been shown to exert anti-inflammatory effects underlying its putative neuroprotective properties in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) mouse model of Parkinson's disease and in the R6/2 mouse model of Huntington's disease (HD). However, contradictory results have recently been reported. We report deleterious effects of minocycline in two phenotypic (toxic) models of Parkinson's disease and HD in monkey and mouse. Of seven MPTP-intoxicated female cynomolgus monkeys (0.2 mg/kg, i.v. until day 15), three received minocycline (200 mg b.i.d.). While placebo-MPTP-treated animals displayed mild parkinsonism at day 15, the minocycline/MPTP-treated animals tended to be more affected (P = 0.057) and showed a greater loss of putaminal dopaminergic nerve endings (P < 0.0001). In the 3-nitropropionic acid (3-NP) mouse model of HD, minocycline (45 mg/kg i.p.) was administered 30 min before each i.p. injection of 3-NP (b.i.d., cumulated dose, 360 mg/kg in 5 days). Mice receiving minocycline exhibited a worsening of the mean motor score with a slower recovery slope, more impaired general activity and significantly deteriorated performances on the rotarod, pole test and beam-traversing tasks. The histopathological outcome demonstrated that minocycline-treated mice presented significantly more severe neuronal cell loss in the dorsal striatum. The effect of minocycline vs. 3-NP was also investigated on hippocampal and cortical cell cultures, minocycline blocked 3-NP-induced neurotoxicity at certain doses (1 mM cortical neurons) but not at higher doses (10 mM). Thus, minocycline may have variable and even deleterious effects in different species and models according to the mode of administration and dose.",
keywords = "1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine, 3-nitropropionic acid, Minocycline, Monkey, Mouse, MPTP",
author = "Elsa Diguet and Fernagut, {Pierre Olivier} and Xing Wei and Yansheng Du and Richard Rouland and Christian Gross and Erwan Bezard and Fran{\cc}ois Tison",
year = "2004",
month = "6",
doi = "10.1111/j.0953-816X.2004.03372.x",
language = "English",
volume = "19",
pages = "3266--3276",
journal = "European Journal of Neuroscience",
issn = "0953-816X",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease

AU - Diguet, Elsa

AU - Fernagut, Pierre Olivier

AU - Wei, Xing

AU - Du, Yansheng

AU - Rouland, Richard

AU - Gross, Christian

AU - Bezard, Erwan

AU - Tison, François

PY - 2004/6

Y1 - 2004/6

N2 - Minocycline has been shown to exert anti-inflammatory effects underlying its putative neuroprotective properties in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) mouse model of Parkinson's disease and in the R6/2 mouse model of Huntington's disease (HD). However, contradictory results have recently been reported. We report deleterious effects of minocycline in two phenotypic (toxic) models of Parkinson's disease and HD in monkey and mouse. Of seven MPTP-intoxicated female cynomolgus monkeys (0.2 mg/kg, i.v. until day 15), three received minocycline (200 mg b.i.d.). While placebo-MPTP-treated animals displayed mild parkinsonism at day 15, the minocycline/MPTP-treated animals tended to be more affected (P = 0.057) and showed a greater loss of putaminal dopaminergic nerve endings (P < 0.0001). In the 3-nitropropionic acid (3-NP) mouse model of HD, minocycline (45 mg/kg i.p.) was administered 30 min before each i.p. injection of 3-NP (b.i.d., cumulated dose, 360 mg/kg in 5 days). Mice receiving minocycline exhibited a worsening of the mean motor score with a slower recovery slope, more impaired general activity and significantly deteriorated performances on the rotarod, pole test and beam-traversing tasks. The histopathological outcome demonstrated that minocycline-treated mice presented significantly more severe neuronal cell loss in the dorsal striatum. The effect of minocycline vs. 3-NP was also investigated on hippocampal and cortical cell cultures, minocycline blocked 3-NP-induced neurotoxicity at certain doses (1 mM cortical neurons) but not at higher doses (10 mM). Thus, minocycline may have variable and even deleterious effects in different species and models according to the mode of administration and dose.

AB - Minocycline has been shown to exert anti-inflammatory effects underlying its putative neuroprotective properties in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) mouse model of Parkinson's disease and in the R6/2 mouse model of Huntington's disease (HD). However, contradictory results have recently been reported. We report deleterious effects of minocycline in two phenotypic (toxic) models of Parkinson's disease and HD in monkey and mouse. Of seven MPTP-intoxicated female cynomolgus monkeys (0.2 mg/kg, i.v. until day 15), three received minocycline (200 mg b.i.d.). While placebo-MPTP-treated animals displayed mild parkinsonism at day 15, the minocycline/MPTP-treated animals tended to be more affected (P = 0.057) and showed a greater loss of putaminal dopaminergic nerve endings (P < 0.0001). In the 3-nitropropionic acid (3-NP) mouse model of HD, minocycline (45 mg/kg i.p.) was administered 30 min before each i.p. injection of 3-NP (b.i.d., cumulated dose, 360 mg/kg in 5 days). Mice receiving minocycline exhibited a worsening of the mean motor score with a slower recovery slope, more impaired general activity and significantly deteriorated performances on the rotarod, pole test and beam-traversing tasks. The histopathological outcome demonstrated that minocycline-treated mice presented significantly more severe neuronal cell loss in the dorsal striatum. The effect of minocycline vs. 3-NP was also investigated on hippocampal and cortical cell cultures, minocycline blocked 3-NP-induced neurotoxicity at certain doses (1 mM cortical neurons) but not at higher doses (10 mM). Thus, minocycline may have variable and even deleterious effects in different species and models according to the mode of administration and dose.

KW - 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine

KW - 3-nitropropionic acid

KW - Minocycline

KW - Monkey

KW - Mouse

KW - MPTP

UR - http://www.scopus.com/inward/record.url?scp=3042755065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042755065&partnerID=8YFLogxK

U2 - 10.1111/j.0953-816X.2004.03372.x

DO - 10.1111/j.0953-816X.2004.03372.x

M3 - Article

VL - 19

SP - 3266

EP - 3276

JO - European Journal of Neuroscience

JF - European Journal of Neuroscience

SN - 0953-816X

IS - 12

ER -